Tags

Type your tag names separated by a space and hit enter

Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
Dig Dis. 2017; 35(6):541-547.DD

Abstract

BACKGROUND

Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers have not been assessed so far.

SUMMARY

Patients (n = 21) receiving Sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV were enrolled in this study. Changes in alanine aminotransferase (ALT) and α-fetoprotein (AFP) levels, platelet (PLT) counts, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI) in both groups were assessed in patients achieving SVR12. Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group. In both groups, while the reduction in ALT levels was significant that of AFP was not. Compared with the baseline, although serum PLT count at the end of treatment (EOT) was significantly higher in the Sofosbuvir plus RBV group, it was significantly lower in the peg-IFN plus RBV group. Although a significant decline in fibrosis markers such as FIB-4 and APRI was observed between the baseline and at EOT in the Sofosbuvir plus RBV group, no significant change of these markers was observed in the peg-IFN plus RBV group. Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Key Message: The treatment with Sofosbuvir plus RBV results in not only a higher SVR, but also improves the liver function and the degree of fibrosis.

Authors+Show Affiliations

Division of Molecular Medicine and Medical Genetics, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

29040986

Citation

Seo, Kayo, et al. "Comparison of Sofosbuvir Plus Ribavirin Treatment With Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2." Digestive Diseases (Basel, Switzerland), vol. 35, no. 6, 2017, pp. 541-547.
Seo K, Kim SK, Kim SR, et al. Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2. Dig Dis. 2017;35(6):541-547.
Seo, K., Kim, S. K., Kim, S. R., Ohtani, A., Kobayashi, M., Kato, A., Morimoto, E., Saijo, Y., Kim, K. I., Imoto, S., Kim, C. W., Yano, Y., Kudo, M., & Hayashi, Y. (2017). Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2. Digestive Diseases (Basel, Switzerland), 35(6), 541-547. https://doi.org/10.1159/000480145
Seo K, et al. Comparison of Sofosbuvir Plus Ribavirin Treatment With Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2. Dig Dis. 2017;35(6):541-547. PubMed PMID: 29040986.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2. AU - Seo,Kayo, AU - Kim,Soo Ki, AU - Kim,Soo Ryang, AU - Ohtani,Aya, AU - Kobayashi,Mana, AU - Kato,Airi, AU - Morimoto,Eri, AU - Saijo,Yuka, AU - Kim,Ke Ih, AU - Imoto,Susumu, AU - Kim,Chi Wan, AU - Yano,Yoshihiko, AU - Kudo,Masatoshi, AU - Hayashi,Yoshitake, Y1 - 2017/10/17/ PY - 2017/10/18/entrez PY - 2017/10/19/pubmed PY - 2018/1/27/medline KW - Chronic hepatitis C genotype 2 KW - Fibrosis marker KW - Hepatocellular carcinoma marker KW - Liver function KW - Sofosbuvir plus ribavirin SP - 541 EP - 547 JF - Digestive diseases (Basel, Switzerland) JO - Dig Dis VL - 35 IS - 6 N2 - BACKGROUND: Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers have not been assessed so far. SUMMARY: Patients (n = 21) receiving Sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV were enrolled in this study. Changes in alanine aminotransferase (ALT) and α-fetoprotein (AFP) levels, platelet (PLT) counts, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI) in both groups were assessed in patients achieving SVR12. Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group. In both groups, while the reduction in ALT levels was significant that of AFP was not. Compared with the baseline, although serum PLT count at the end of treatment (EOT) was significantly higher in the Sofosbuvir plus RBV group, it was significantly lower in the peg-IFN plus RBV group. Although a significant decline in fibrosis markers such as FIB-4 and APRI was observed between the baseline and at EOT in the Sofosbuvir plus RBV group, no significant change of these markers was observed in the peg-IFN plus RBV group. Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Key Message: The treatment with Sofosbuvir plus RBV results in not only a higher SVR, but also improves the liver function and the degree of fibrosis. SN - 1421-9875 UR - https://www.unboundmedicine.com/medline/citation/29040986/Comparison_of_Sofosbuvir_Plus_Ribavirin_Treatment_with_Pegylated_Interferon_Plus_Ribavirin_Treatment_for_Chronic_Hepatitis_C_Genotype_2_ L2 - https://www.karger.com?DOI=10.1159/000480145 DB - PRIME DP - Unbound Medicine ER -